Analyst Rating Update on Intercept Pharmaceuticals (ICPT)

Intercept Pharmaceuticals (ICPT) : Zacks Investment Research ranks Intercept Pharmaceuticals (ICPT) as 3, which is a Hold recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. Not everyone is convinced about the stocks future, hence, the stock receives 1 Sell recommendation. 2 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.1, which indicates as a Buy.

Intercept Pharmaceuticals (ICPT) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $332 and the lowest price target forecast is $58. The average forecast of all the analysts is $193.5 and the expected standard deviation is $77.05.

For the current week, the company shares have a recommendation consensus of Buy.


Intercept Pharmaceuticals (NASDAQ:ICPT): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $170.44 and $169.79 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $174.24. The buying momentum continued till the end and the stock did not give up its gains. It closed at $172.59, notching a gain of 1.24% for the day. The total traded volume was 755,484 . The stock had closed at $170.47 on the previous day.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry. The Companys product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The Company is also developing other products INT-767 and INT-777 for the treatment of fibrosis and type 2 diabetes. OCA has been tested in five placebo-controlled clinical trials, including a completed Phase III clinical trial in patients with primary biliary cirrhosis (PBC) and two Phase II clinical trials in patients with nonalcoholic fatty liver disease (NAFLD), and nonalcoholic steatohepatitis (NASH). OCA met the primary efficacy endpoint in each of these trials with statistical significance.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.